Eam Global Investors LLC Krystal Biotech, Inc. Transaction History

Eam Global Investors LLC

$435 Million
Q3 2024

A detailed history of Eam Global Investors LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Eam Global Investors LLC holds 28,976 shares of KRYS stock, worth $4.86 Million. This represents 1.21% of its overall portfolio holdings.

Number of Shares

28,976

Previous 28,843 0.46%

Holding current value

$4.86 Million

Previous $5.3 Million 0.51%

% of portfolio

1.21%

Previous 1.32%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$174.7 - $213.66 $23,235 - $28,416	133 Added 0.46%	28,976 $5.27 Million
Q2 2024 Aug 12, 2024	BUY	$153.12 - $183.64 $153 - $183	1 Added 0.0%	28,843 $5.3 Million
Q1 2024 May 13, 2024	BUY	$108.01 - $179.35 $3.12 Million - $5.17 Million	28,842 New	28,842 $5.13 Million
Q3 2023 Nov 13, 2023	SELL	$108.51 - $130.22 $613,407 - $736,133	-5,653 Reduced 16.07%	29,517 $3.42 Million
Q2 2023 Aug 11, 2023	BUY	$78.48 - $130.32 $2.76 Million - $4.58 Million	35,170 New	35,170 $4.13 Million
Q2 2022 Aug 12, 2022	SELL	$48.93 - $73.47 $17,321 - $26,008	-354 Reduced 1.61%	21,605 $1.42 Million
Q4 2021 Feb 11, 2022	BUY	$39.81 - $88.24 $874,187 - $1.94 Million	21,959 New	21,959 $1.54 Million
Q2 2020 Aug 13, 2020	SELL	$37.03 - $60.0 $1.11 Million - $1.8 Million	-30,065 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$35.02 - $65.64 $175 - $328	-5 Reduced 0.02%	30,065 $1.3 Million
Q4 2019 Feb 10, 2020	SELL	$33.17 - $65.23 $373,461 - $734,424	-11,259 Reduced 27.24%	30,070 $1.67 Million
Q3 2019 Nov 13, 2019	BUY	$34.72 - $51.3 $284,426 - $420,249	8,192 Added 24.72%	41,329 $1.44 Million
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $901,326 - $1.37 Million	33,137 New	33,137 $1.33 Million

Others Institutions Holding KRYS

# of Institutions

311

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.3B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Global Investors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Global Investors LLC with notifications on news.

Account

Eam Global Investors LLC Krystal Biotech, Inc. Transaction History